Title of article
Targeted Lung Cancer Treatments and Eye Metastasis
Author/Authors
ZAROGOULIDIS, Paul Department-Oncology Unit - “G. Papanikolaou” General Hospital - Aristotle University of Thessaloniki, Thessaloniki, Greece , BAKA, Sofia Department - European Interbalkan Medical Center Thessaloniki, Greece , LABAKI, Sofia Department-Oncology Unit - “G. Papanikolaou” General Hospital - Aristotle University of Thessaloniki, Thessaloniki, Greece , LAZARIDIS, George Oncology Department - ``G. Papageorgiou`` , Georgia TRAKADA Department of Clinical Therapeutics - National and Kapodistrian University of Athens School of Medicine - Alexandra Hospital, Athens, Greece
Pages
4
From page
10
To page
13
Abstract
Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they are effective against eye metastasis.
Keywords
Lung cancer , Epidermal Growth Factor Receptor , Anaplastic Lymphoma Kinase , Serine/Threonine-Protein Kinase B-Raf , Proto-Oncogene Tyrosine-Protein Kinase ROS , C-Met Proto-Oncogene Protein , RET Proto-Oncogene Protein
Journal title
Medical Hypothesis, Discovery & Innovation Ophthalmology
Serial Year
2017
Record number
2523004
Link To Document